After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...